FY2024 EPS Estimates for Exact Sciences Cut by William Blair

Exact Sciences Co. (NASDAQ:EXAS) – Investment analysts at William Blair dropped their FY2024 earnings per share (EPS) estimates for Exact Sciences in a research report issued to clients and investors on Thursday, November 21st. William Blair analyst A. Brackmann now anticipates that the medical research company will post earnings per share of ($1.07) for the year, down from their prior estimate of ($0.81). William Blair has a “Outperform” rating on the stock. The consensus estimate for Exact Sciences’ current full-year earnings is ($1.13) per share. William Blair also issued estimates for Exact Sciences’ Q4 2024 earnings at ($0.28) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.15 EPS and FY2025 earnings at ($0.19) EPS.

EXAS has been the subject of several other reports. Jefferies Financial Group upped their target price on Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Benchmark cut their price target on shares of Exact Sciences from $67.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Stifel Nicolaus cut their price objective on Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Citigroup decreased their target price on Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, The Goldman Sachs Group decreased their target price on shares of Exact Sciences from $75.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $74.47.

Exact Sciences Trading Up 4.2 %

EXAS opened at $55.14 on Monday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. The firm’s fifty day moving average price is $64.51 and its 200 day moving average price is $55.85. Exact Sciences has a 12-month low of $40.62 and a 12-month high of $79.62. The stock has a market capitalization of $10.21 billion, a PE ratio of -47.13 and a beta of 1.27.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The firm had revenue of $708.66 million for the quarter, compared to analysts’ expectations of $716.80 million. The firm’s revenue for the quarter was up 12.8% on a year-over-year basis.

Institutional Trading of Exact Sciences

A number of large investors have recently bought and sold shares of EXAS. Huntington National Bank boosted its holdings in shares of Exact Sciences by 838.1% in the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after buying an additional 352 shares during the period. Itau Unibanco Holding S.A. bought a new stake in shares of Exact Sciences in the second quarter valued at about $29,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Exact Sciences during the third quarter worth about $34,000. Capital Performance Advisors LLP bought a new stake in Exact Sciences in the 3rd quarter valued at approximately $35,000. Finally, Vestor Capital LLC acquired a new position in Exact Sciences during the 3rd quarter worth approximately $46,000. 88.82% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of the company’s stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $70.00, for a total transaction of $65,030.00. Following the completion of the sale, the executive vice president now owns 12,758 shares in the company, valued at approximately $893,060. The trade was a 6.79 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Kevin T. Conroy bought 19,500 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were bought at an average price of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the transaction, the chief executive officer now directly owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. This trade represents a 1.85 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.36% of the company’s stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.